XTRA:BAYNPharmaceuticals
Bayer’s Lynkuet Approval Adds New Thread To Pharmaceuticals Story In US
The FDA has approved Bayer's nonhormonal menopause drug Lynkuet for treating hot flashes and night sweats in the US.
Lynkuet has now launched in the US market, supported by a rapid direct to consumer marketing campaign.
The product expands Bayer's pharmaceutical portfolio into nonhormonal menopause care, targeting an identified unmet medical need.
Bayer (XTRA:BAYN) is adding Lynkuet to its portfolio at a time when the shares trade around €38.26 and the stock shows mixed medium term...